The intravenous anaesthetic ketamine is a racemic mixture of two equimolar doses of enantiomers. After stereoselective separation, the right-handed S(+)-isomer is now clinically available. Since anaesthetic and analgesic pharmacological studies have shown that S(+)-ketamine is approximately two times as potent as racemic ketamine, the clinical effects of S(+)-ketamine were evaluated in comparison to ketamine-racemate at dose relation of 1:2 in several therapeutic investigations. The studies disclosed that both drugs caused a similar activation of the endocrine stress response and a comparable stimulation of the sympathoadrenergic system. However, application of S(+)-ketamine was associated with a remarkably smoother emergence period, a profound postoperative analgesia, a more rapid recovery of cerebral functions, and a greater preference by the study persons. The incidence of psychotomimetic phenomena appeared to be negligibly less after S(+)-ketamine in comparison to racemic ketamine, but their quality was described as far less unpleasant. Clinical use of S(+)-ketamine administered at one-half of the usual dose is thus not only associated with a reduction of undesirable adverse effects without altering ketamine's anaesthetic and analgesic potency, but also offers distinctive improvements due to the reduced drug load. Moreover, increasing experimental evidence supports a remarkable neuroprotective effect of S(+)-ketamine, which may become a promising drug for new therapeutic approaches to neuroprotection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.